NASDAQ:GENE Genetic Technologies (GENE) Stock Price, News & Analysis → The attacks will come for me after releasing this… (From Porter & Company) (Ad) Free GENE Stock Alerts $1.82 -0.01 (-0.55%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$1.78▼$1.8550-Day Range$1.70▼$3.3652-Week Range$1.67▼$4.95Volume32,008 shsAverage Volume45,031 shsMarket Capitalization$8.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Genetic Technologies alerts: Email Address Ad Porter & CompanyThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. About Genetic Technologies Stock (NASDAQ:GENE)Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.Read More GENE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GENE Stock News HeadlinesJune 14 at 5:44 AM | americanbankingnews.comGenetic Technologies Limited (NASDAQ:GENE) Short Interest Up 495.3% in MayMay 29, 2024 | tmcnet.comExpressionEdits Raises $13M in Seed Funding to Advance Protein Expression Using AI-Driven Intronization TechnologyMay 29, 2024 | finance.yahoo.comGTG Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian CancerMay 28, 2024 | msn.comAdvancing Targeted Genome Editing with Base and Prime Editing TechnologiesMay 28, 2024 | msn.comGenetic mosaicism more common than thought, study showsMay 28, 2024 | msn.comHistorical rape charge after police use DNA technologyMay 14, 2024 | msn.comGenetic technologies: AgResearch to showcase opportunities at FieldaysMay 12, 2024 | msn.comMichael J. Sandel, philosopher: ‘I resist the tendency to see technology as an autonomous force that we cannot control’May 6, 2024 | au.investing.comGenetic Technologies unlocks access to huge network with Wellworks sales and marketing agreementMay 2, 2024 | msn.comGenetic testing helps investigators identify 1989 homicide victim in western MassachusettsApril 30, 2024 | msn.comScientists use cloning technology to revive endangered species: 'Conservationists have worked very hard to bring them back'April 30, 2024 | msn.comAI-MARRVEL: A leap forward in diagnosing genetic diseases with over 98% precisionApril 30, 2024 | finance.yahoo.comAppendix 4C & Quarterly Business Update – March 2024April 30, 2024 | globenewswire.comAppendix 4C & Quarterly Business Update – March 2024April 29, 2024 | msn.comResearchers identify genetic cause of rare movement disorderApril 29, 2024 | msn.comScientists' research on RNA editing illuminates possible lifesaving treatments for genetic diseasesApril 29, 2024 | finance.yahoo.comBio-E Introduces Pearly White Essence Drink, Enhancing Skin Brightness with Advanced Genetic TechnologyApril 27, 2024 | msn.comMachine learning-powered robot streamlines genetic research processApril 26, 2024 | msn.comExperts develop way to harness CRISPR technology to deal with antimicrobial resistanceApril 26, 2024 | msn.comNew Zealand: How gene technology is changing future of foodApril 26, 2024 | msn.comResearchers Unveil Automated Embryo Injection Technology with Broad ApplicationsApril 26, 2024 | msn.comUnveiling the genetic blueprint of safflowerApril 23, 2024 | msn.comSaving parrots in the illegal wildlife trade with DNA technologyApril 22, 2024 | globenewswire.comGenetic Technologies Announces Closing of US$2 Million Registered Direct OfferingApril 22, 2024 | msn.comNeurolentech signs technology access partnership with Kaerus Bioscience to advance neurodevelopmental disorder researchSee More Headlines Receive GENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/14/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GENE CUSIPN/A CIK1166272 Webwww.gtgcorporate.com Phone(138) 412-7000Fax011-61-3-8412-7040Employees60Year Founded1989Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.02 Current Ratio1.67 Quick Ratio1.55 Sales & Book Value Annual Sales$5.85 million Price / Sales1.39 Cash FlowN/A Price / Cash FlowN/A Book Value$1.95 per share Price / Book0.95Miscellaneous Outstanding Shares4,410,000Free Float4,122,000Market Cap$8.16 million OptionableOptionable Beta1.14 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Simon MorrissChief Executive OfficerMr. Carl S. Stubbings BScChief Commercial OfficerMr. Kevin CamilleriChief Executive Officer of EasyDNAMs. Kathryn J. E. Andrews B.Com. (Age 57)C.P.A., M.A.I.C.D., CFO & Company Secretary Mr. Paul Keith Mathieson Viney B. BusFCI, FCPA, FGIA, ConsultantKey CompetitorsBrainstorm Cell TherapeuticsNASDAQ:BCLISAB BiotherapeuticsNASDAQ:SABSCortexymeNASDAQ:CRTXZIVO BioscienceNASDAQ:ZIVOAIM ImmunoTechNYSE:AIMView All CompetitorsInstitutional OwnershipBNP Paribas Financial MarketsBought 9,100 shares on 5/1/2024Ownership: 0.236%View All Institutional Transactions GENE Stock Analysis - Frequently Asked Questions How have GENE shares performed in 2024? Genetic Technologies' stock was trading at $2.40 at the beginning of the year. Since then, GENE stock has decreased by 24.2% and is now trading at $1.82. View the best growth stocks for 2024 here. Are investors shorting Genetic Technologies? Genetic Technologies saw a increase in short interest in May. As of May 31st, there was short interest totaling 126,200 shares, an increase of 495.3% from the May 15th total of 21,200 shares. Based on an average trading volume of 57,800 shares, the short-interest ratio is currently 2.2 days. View Genetic Technologies' Short Interest. When did Genetic Technologies' stock split? Genetic Technologies shares reverse split before market open on Monday, December 4th 2023. The 1-5 reverse split was announced on Monday, December 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of Genetic Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genetic Technologies investors own include Vascular Biogenics (VBLT), Caladrius Biosciences (CLBS), Inovio Pharmaceuticals (INO), Novavax (NVAX), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Atossa Therapeutics (ATOS), FuelCell Energy (FCEL) and Heat Biologics (HTBX). Who are Genetic Technologies' major shareholders? Genetic Technologies' stock is owned by many different institutional and retail investors. Top institutional investors include BNP Paribas Financial Markets (0.24%). How do I buy shares of Genetic Technologies? Shares of GENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GENE) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersPresident KamalaThe sneaky (yet 100% legal) way for Obama to return to power The ONLY way Democrats can keep the White Hous...Stansberry Research | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genetic Technologies Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Genetic Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.